Long-acting bronchodilators improve Health Related Quality of Life in patients with COPD

Respiratory Medicine

Volumn 107, Issue 10, 2013, Pages 1465-1480

  Braido, Fulvio ^a,c   Baiardini, Ilaria ^a   Cazzola, Mario ^b   Brusselle, Guy ^b   Marugo, Fiorenza ^a   Canonica, Giorgio Walter ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

COPD; Health status; Long acting bronchodilators; Quality of life

Indexed keywords

ACLIDINIUM BROMIDE; ARFORMOTEROL; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; FORMOTEROL FUMARATE; GLYCOPYRRONIUM BROMIDE; HISTAMINE H1 RECEPTOR ANTAGONIST; INDACATEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TULOBUTEROL; VILANTEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; DISEASE SEVERITY; DRUG EFFICACY; DRY POWDER INHALER; EXERCISE; FOLLOW UP; HEALTH STATUS; HUMAN; MAINTENANCE THERAPY; OXYGEN THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY REHABILITATION; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHORT FORM 36; SINGLE DRUG DOSE; SMOKING HABIT; SOCIAL STATUS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

COPD; HEALTH STATUS; LONG-ACTING BRONCHODILATORS; QUALITY OF LIFE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84884819856     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.08.007     Document Type: Review

References (88)

1. H. Schipper, J. Clinch, and C.L.M. Olweny Quality of life studies: definitions and conceptual issues B. Spilker, Quality of life and pharmacoeconomics in clinical trials 1990 Lippincot-Raven Press Philadelphia 11 23
2. J.A. Spertus, J. Tooley, P. Jones, C. Poston, E. Mahoney, P. Deedwania, S. Hurley, B. Pitt, and W.S. Weintraub Expanding the outcomes in clinical trials of heart failure: the quality of life and economic components of EPHESUS (E Plerenone's neuro Hormonal Efficacy and Survival Study) Am Heart J 143 2002 636 642
3. I.B. Wilson, and P.D. Cleary Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes JAMA 4 273 1995 59 65
4. J. De Vries Quality of life assessment A.J.J.N. Vingerhoets, Assessment in behavioural medicine 2001 Brunner-Routledge Hove, UK 353 370
5. J.E. Ware, K.K. Snow, M. Kosinski, and B. Gandek SF-36 Health Survey. Manual and interpretation guide 1993 Health Institute, New England Medical Center Boston
6. P.W. Jones, F.H. Quirk, C.M. Baveystock, and P. Littlejohns A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire Am Rev Respir Dis 145 1992 1321 1327
7. M. Cazzola, W. MacNee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, P.J. Barnes, V. Brusasco, P.S. Burge, P.M. Calverley, B.R. Celli, P.W. Jones, D.A. Mahler, B. Make, M. Miravitlles, C.P. Page, P. Palange, D. Parr, M. Pistolesi, S.I. Rennard, M.P. Rutten-van Mölken, R. Stockley, S.D. Sullivan, J.A. Wedzicha, E.F. Wouters, American Thoracic Society, and European Respiratory Society Task Force on outcomes of COPD Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 2008 416 469
8. J.R. Curtis, and D.L. Patrick The assessment of health status among patients with COPD Eur Respir J 41 2003 36 45
9. P.W. Jones, G. Brusselle, R.W. Negro, M. Ferrer, P. Kardos, M.L. Levy, T. Perez, J.J. Cataluña, T. van der Molen, L. Adamek, and N. Banik Patient-centred assessment of COPD in primary care: experience from a cross-sectional study of health-related quality of life in Europe Prim Care Respir J 21 2012 329 336
10. P.W. Jones Activity limitation and quality of life in COPD COPD 4 2007 273 278
11. F. Braido, I. Baiardini, S. Menoni, A.M. Bagnasco, F. Balbi, S. Bocchibianchi, S. Balestracci, M.G. Piroddi, and G.W. Canonica Disability in COPD and its relationship to clinical and patient-reported outcomes Curr Med Res Opin 27 2011 981 986
12. F. Braido, I. Baiardini, S. Balestracci, S. Menoni, F. Balbi, G. Ferraioli, S. Bocchibianchi, and G.W. Canonica Chronic obstructive pulmonary disease patient well-being and its relationship with clinical and patient-reported outcomes: a real-life observational study Respiration 82 2011 335 340
13. US Department of Health and Human Services FDA Center for Drug Evaluation and Research, and US Department of Health and Human Services FDA Center for Biologics Evaluation and Research and US Department of Health and Human Services FDA Center for Devices and Radiological Health Guidance for Industry: patient reported outcome measures: use in medical product development to support labelling claims: draft guidance Health Qual Life Outcome. 4 2006 79
14. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQoL) measures in the evaluation of medicinal products 2005 European Medicines Agency. Committee for medicinal products for human use (CHMP) European Medicines Agency website. Available at: http://www.emea.europa.eu/ pdfs/human/ewp/13939104en.pdf Accessed June 2009
15. Preamble to the constitution of the world health organization as adopted by the international health conference, New York, 19 June-22 July 1946; signed on 22 July 1946 by the representatives of 61 States (Official Records of the World Health Organization, no. 2, p. 100) and entered into force on 7 April 1948.
16. F. Braido, P.J. Bousquet, Z. Brzoza, G.W. Canonica, E. Compalati, A. Fiocchi, W. Fokkens, R. Gerth van Wijk, S. La Grutta, C. Lombardi, M. Maurer, A.M. Pinto, E. Ridolo, G.E. Senna, I. Terreehorst, A. Todo Bom, J. Bousquet, T. Zuberbier, and I. Baiardini Specific recommendations for PROs and HRQoL assessment in allergic rhinitis and/or asthma: a GA(2)LEN taskforce position paper Allergy 65 2010 959 968
17. G.H. Guyatt, A.D. Oxman, G. Vist, R. Kunz, Y. Falck-Ytter, and P. Alonso-Coello Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations BMJ 336 2008 924 926
18. Global strategy for the diagnosis, management and prevention of chronic pulmonary disease 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) http://www.goldcopd.org/Guidelines/guidelines-resources.html
19. J. O'Reilly, M.M. Jones, and J. Parnham Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance BMJ 340 2010 c3134
20. G.H. Guyatt, D. Osoba, A.W. Wu, K.W. Wyrwich, G.R. Norman Clinical Significance Consensus Meeting Group Methods to explain the clinical significance of health status measures Mayo Clin Proc 77 2002 371 383
21. Global strategy for diagnosis, management, and prevention of COPD 2009 update http://www.goldcopd.org
22. M. Campbell, A. Eliraz, G. Johansson, G. Tornling, U. Nihlén, T. Bengtsson, and K.F. Rabe Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease Respir Med 99 2005 1511 1520
23. R.A. Baumgartner, N.A. Hanania, W.J. Calhoun, S.A. Sahn, K. Sciarappa, and J.P. Hanrahan Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial Clin Ther 29 2007 261 278
24. R. Dahl, L.A. Greefhorst, D. Nowak, V. Nonikov, A.M. Byrne, M.H. Thomson, D. Till, G. Della Cioppa Formoterol in Chronic Obstructive Pulmonary Disease I Study Group Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 778 784
25. M. Wadbo, C.G. Löfdahl, K. Larsson, B.E. Skoogh, G. Tornling, E. Arweström, T. Bengtsson, K. Ström, and Swedish Society of Respiratory Medicine Source effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study Eur Respir J 20 2002 1138 1146
26. A. Rossi, P. Kristufek, B.E. Levine, M.H. Thomson, D. Till, J. Kottakis, G. Della Cioppa Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD Chest 121 2002 1058 1069
27. N.A. Hanania, J.F. Donohue, H. Nelson, K. Sciarappa, E. Goodwin, R.A. Baumgartner, and J.P. Hanrahan The safety and efficacy of arformoterol and formoterol in COPD COPD 7 2010 17 31
28. N.J. Gross, H.S. Nelson, R.J. Lapidus, L. Dunn, L. Lynn, M. Rinehart, K. Denis-Mize Formoterol Study Group Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients Respir Med 102 2008 189 197
29. T. Welte, P. Metzenauer, and U. Hartmann Once versus twice daily formoterol via novolizer for patients with moderate to severe COPD-a double-blind, randomised, controlled trial Pulm Pharmacol Ther 21 2008 4 13
30. H.J. Schünemann, M. Puhan, R. Goldstein, R. Jaeschke, and G.H. Guyatt Measurement properties and interpretability of the chronic respiratory disease questionnaire (CRQ) COPD 2 2005 81 89
31. S.I. Rennard, W. Anderson, R. ZuWallack, J. Broughton, W. Bailey, M. Friedman, M. Wisniewski, and K. Rickard Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 163 2001 1087 1092
32. G. Di Lorenzo, G. Morici, A. Drago, M.E. Pellitteri, P. Mansueto, M. Melluso, F. Norrito, L. Squassante, A. Fasolo SLMT02 Italian Study Group Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease Clin Ther 20 1998 1130 1148
33. M. Taccola, L. Bancalari, G. Ghignoni, and P.L. Paggiaro Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease Monaldi Arch Chest Dis 54 1999 302 306
34. P.W. Jones, and T.K. Bosh Quality of life changes in COPD patients treated with salmeterol Am J Respir Crit Care Med 155 1997 1283 1289
35. R.K. Gupta, and S.K. Chhabra An evaluation of salmeterol in the treatment of chronic obstructive pulmonary diseases Indian J Chest Dis Allied Sci 44 2002 165 172
36. K.R. Chapman, P. Arvidsson, A.G. Chuchalin, D.P. Dhillon, P. Faurschou, R.S. Goldstein, A.F. Kuipers International study group The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease Can Respir J 9 2002 178 185
37. R.A. Stockley, N. Chopra, and L. Rice Addition of salmeterol to existing treatment in patients with COPD: a 12 month study Thorax 61 2006 122 128
38. G. Boyd, A.H. Morice, J.C. Pounsford, M. Siebert, N. Peslis, and C. Crawford An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) Eur Respir J 10 1997 815 821
39. P.W. Jones, K. Wilson, and S. Sondhi Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation Respir Med 97 2003 20 26
40. J.F. Donohue, C. Fogarty, J. Lötvall, D.A. Mahler, H. Worth, A. Yorgancioglu, A. Iqbal, J. Swales, R. Owen, M. Higgins, B. Kramer INHANCE Study Investigators Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
41. R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, D. Jack, P. Bleasdale, R. Owen, M. Higgins, B. Kramer INVOLVE (Indacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
42. 2-agonist, in subjects with COPD: a randomized, placebo-controlled study Chest 140 2011 68 75
43. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, C. Lassen, B. Kramer INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-μg Doses with COPD Patients) study investigators Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 37 2011 273 279
44. E.M. Kerwin, M.H. Gotfried, D. Lawrence, C. Lassen, and B. Kramer Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies Clin Ther 33 2011 1974 1984
45. M. Kinoshita, S.H. Lee, L.W. Hang, M. Ichinose, M. Hosoe, N. Okino, N. Prasad, B. Kramer, Y. Fukuchi Indacaterol Asian COPD Study Investigators Efficacy and safety of indacaterol 150 and 300 μg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study Respirology 17 2012 379 389
46. A. D'Urzo, G.T. Ferguson, J.A. van Noord, K. Hirata, C. Martin, R. Horton, Y. Lu, D. Banerji, and T. Overend Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respir Res 12 2011 156
47. E. Kerwin, J. Hébert, N. Gallagher, C. Martin, T. Overend, V.K. Alagappan, Y. Lu, and D. Banerji Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur Respir J 40 2012 1106 1114
48. P. Chanez, P.S. Burge, R. Dahl, J. Creemers, A. Chuchalin, R. Lamarca, and E. Garcia Gil Aclidinium bromide provides long-acting bronchodilation in patients with COPD Pulm Pharmacol Ther 23 2010 15 21
49. P.W. Jones, S.I. Rennard, A. Agusti, P. Chanez, H. Magnussen, L. Fabbri, J.F. Donohue, E.D. Bateman, N.J. Gross, R. Lamarca, C. Caracta, and E.G. Gil Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease Respir Res 12 2011 55
50. P.W. Jones, D. Singh, E.D. Bateman, A. Agusti, R. Lamarca, G. de Miquel, R. Segarra, C. Caracta, and E. Garcia Gil Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Eur Respir J 40 2012 830 836
51. W. Vincken, J.A. van Noord, A.P. Greefhorst, T.A. Bantje, S. Kesten, L. Korducki, P.J. Cornelissen Dutch/Belgian Tiotropium Study Group Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium Eur Respir J 19 2002 209 216
52. J.F. Donohue, J.A. van Noord, E.D. Bateman, S.J. Langley, A. Lee, T.J. Witek Jr., S. Kesten, and L.A. Towse 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol Chest 122 2002 47 55
53. V. Brusasco, R. Hodder, M. Miravitlles, L. Korducki, L. Towse, and S. Kesten Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD Thorax 58 2003 399 404
54. R. Casaburi, D.A. Mahler, P.W. Jones, A. Wanner, P.G. San, R.L. ZuWallack, S.S. Menjoge, C.W. Serby, and T. Witek Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Eur Respir J 19 2002 217 224
55. R. Casaburi, D. Kukafka, C.B. Cooper, T.J. Witek Jr., and S. Kesten Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD Chest 127 2005 809 817
56. H. Covelli, S. Bhattacharya, C. Cassino, C. Conoscenti, and S. Kesten Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease Pharmacotherapy 25 2005 1708 1718
57. C. Verkindre, F. Bart, B. Aguilaniu, F. Fortin, J.C. Guérin, C. Le Merre, P. Iacono, and G. Huchon The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease Respiration 73 2006 420 427
58. S.W. Um, C.G. Yoo, Y.W. Kim, S.K. Han, and Y.S. Shim The combination of tiotropium and budesonide in the treatment of chronic obstructive pulmonary disease J Korean Med Sci 22 2007 839 845
59. C.K. Chan, F. Maltais, C. Sigouin, J.M. Haddon, G.T. Ford SAFE Study Group A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease Can Respir J 14 2007 465 472
60. G. Johansson, A. Lindberg, K. Romberg, L. Nordström, F. Gerken, and A. Roquet Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD Prim Care Respir J 17 2008 169 175
61. N. Ambrosino, K. Foglio, G. Balzano, P.L. Paggiaro, P. Lessi, S. Kesten Tiotropium Multicentric Italian Study Group Tiotropium and exercise training in COPD patients: effects on dyspnea and exercise tolerance Int J Chron Obstruct Pulmon Dis 3 2008 771 780
62. A.B. Tonnel, T. Perez, J.M. Grosbois, C. Verkindre, M.L. Bravo, M. Brun TIPHON study group Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD Int J Chron Obstruct Pulmon Dis 3 2008 301 310
63. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, M. Decramer UPLIFT Study Investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
64. K. Kurashima, K. Hara, K. Yoneda, T. Kanauchi, N. Kagiyama, D. Tokunaga, N. Takayanagi, M. Ubukata, and Y. Sugita Changes in lung function and health status in patients with COPD treated with tiotropium or salmeterol plus fluticasone Respirology 14 2009 239 244
65. E. Bateman, D. Singh, D. Smith, B. Disse, L. Towse, D. Massey, J. Blatchford, D. Pavia, and R. Hodder Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studies Int J Chron Obstruct Pulmon Dis 5 2010 197 208
66. E.D. Bateman, D. Tashkin, N. Siafakas, R. Dahl, L. Towse, D. Massey, D. Pavia, and N.S. Zhong A one-year trial of tiotropium Respimat plus usual therapy in COPD patients Respir Med 104 2010 1460 1472
67. M. Hoshino, and J. Ohtawa Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease Respirology 16 2011 95 101
68. T. Abe, Y. Setoguchi, Y. Kono, Y. Togashi, S. Sugiyama, M. Tanakadate, S. Soeda, M. Nakai, N. Sugiyama, A. Fujiwara, K. Yamaguchi, A. Yamaguchi, and N. Kurita Effects of inhaled tiotropium plus transdermal tulobuterol versus tiotropium alone on impulse oscillation system (IOS)-assessed measures of peripheral airway resistance and reactance, lung function and quality of life in patients with COPD: a randomized crossover study Pulm Pharmacol Ther 24 2011 617 624
69. S.G. Adams, A. Anzueto, D.D. Briggs Jr., I. Leimer, and S. Kesten Evaluation of withdrawal of maintenance tiotropium in COPD Respir Med 103 2009 1415 1420
70. S.G. Adams, A. Anzueto, D.D. Briggs Jr., S.S. Menjoge, and S. Kesten Tiotropium in COPD patients not previously receiving maintenance respiratory medications Respir Med 2006 1001495 1001503
71. B. Celli, M. Decramer, S. Kesten, D. Liu, S. Mehra, D.P. Tashkin UPLIFT Study Investigators Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 180 2009 948 955
72. M. Decramer, B. Celli, S. Kesten, T. Lystig, S. Mehra, D.P. Tashkin UPLIFT investigators Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial Lancet 374 2009 1171 1178
73. D.P. Tashkin, B. Celli, S. Kesten, T. Lystig, S. Mehra, and M. Decramer Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial Eur Respir J 35 2010 287 294
74. T. Troosters, B. Celli, T. Lystig, S. Kesten, S. Mehra, D.P. Tashkin, and M. Decramer Uplift investigato tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT trial Eur Respir J 36 2010 65 73
75. D. Tashkin, B. Celli, S. Kesten, T. Lystig, and M. Decramer Effect of tiotropium in men and women with COPD: results of the 4-year UPLIFT trial Respir Med 104 2010 1495 1504
76. S.D. Aaron, K.L. Vandemheen, D. Fergusson, F. Maltais, J. Bourbeau, R. Goldstein, M. Balter, D. O'Donnell, A. McIvor, S. Sharma, G. Bishop, J. Anthony, R. Cowie, S. Field, A. Hirsch, P. Hernandez, R. Rivington, J. Road, V. Hoffstein, R. Hodder, D. Marciniuk, D. McCormack, G. Fox, G. Cox, H.B. Prins, G. Ford, D. Bleskie, S. Doucette, I. Mayers, K. Chapman, N. Zamel, M. FitzGerald, and Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial Ann Intern Med 146 2007 545 555
77. D.P. Tashkin, M. Littner, C.P. Andrews, L. Tomlinson, M. Rinehart, and K. Denis-Mize Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial Respir Med 102 2008 479 487
78. C. Vogelmeier, P. Kardos, S. Harari, S.J. Gans, S. Stenglein, and J. Thirlwell Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study Respir Med 102 2008 1511 1520
79. N.A. Hanania, A. Boota, E. Kerwin, L. Tomlinson, and K. Denis-Mize Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide Drugs 69 2009 1205 1216
80. D.P. Tashkin, J. Pearle, D. Iezzoni, and S.T. Varghese Formoterol and tiotropium compared with tiotropium alone for treatment of COPD COPD 6 2009 17 25
81. C.F. Vogelmeier, E.D. Bateman, J. Pallante, V.K.T. Alagappan, P. D'Andrea, H. Chen, and D.F. Banerji Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study Lancet Resp Med 1 2013 51 60
82. C. Karner, J. Chong, and P. Poole Tiotropium versus placebo for chronic obstructive pulmonary disease Cochrane Database Syst Rev 7 2012 Jul 11 CD009285
83. P.W. Jones, N. Barnes, C. Vogelmeier, D. Lawrence, and B. Kramer Efficacy of indacaterol in the treatment of patients with COPD Prim Care Respir J 20 2011 380 388
84. J. Chong, C. Karner, and P. Poole Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease Cochrane Database Syst Rev 9 2012 Sep 12 CD009157
85. S.W. Weldam, M.J. Schuurmans, R. Liu, and J.W. Lammers Evaluation of quality of life instruments for use in COPD care and research: a systematic review Int J Nurs Stud 50 2013 May 688 707
86. I.A. Yang, M.S. Clarke, E.H. Sim, and K.M. Fong Inhaled corticosteroids for stable chronic obstructive pulmonary disease Cochrane Database Syst Rev 7 2012 Jul CD00299
87. T. van der Molen, and M. Cazzola Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes Prim Care Respir J 21 2012 Mar 101 108
88. C. Karner, and C.J. Cates Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease Cochrane Database Syst Rev 4 2012 CD008989